Better Health for All

Cardiol Therapeutics' lead product, CardiolRx™, has demonstrated exceptional health benefits in clinical trials for recurrent pericarditis. Phase II data showed a mean reduction in patient-reported pericarditis pain from 5.8 to 1.5 on a 0-10 scale at 26 weeks, a decrease in pericarditis episodes per year from 5.8 to 0.9, and normalization of CRP levels in 80% of patients at 8 weeks.

The company's entire business is devoted to developing therapies for inflammatory heart disease, including acute myocarditis and heart failure. CardiolRx™ was found to be safe and well-tolerated in the Phase II MAvERIC-Pilot study, with 89% of patients progressing to an extension period. The company has received Orphan Drug Designation from the US FDA for pericarditis treatment. There is no evidence of revenue from products with negative health outcomes. The company is conducting clinical trials, including a pivotal Phase III MAVERIC trial, but specific details on ethical conduct, such as diversity in trial populations or full data transparency, are not provided. Information regarding patent flexibility is also not available.

Fair Trade & Ethical Sourcing

No specific, concrete data points or explicit information regarding fair trade certifications, supplier audit frequency for ethical sourcing, forced or child labor incidents, multi-tier traceability coverage, remediation speed for violations, ethical clause coverage in supplier contracts, materials risk index, or supplier diversity spend were found in the provided articles. While one article mentions that CardiolRx is 'manufactured under cGMP',

which implies a level of quality control and material traceability, it does not provide a quantifiable percentage of suppliers with traceable provenance data as required by the rubric for the 'traceability_coverage' KPI. The documents primarily focus on financial performance, corporate governance, and product manufacturing standards, which do not directly address the quantitative metrics required for this assessment.

Honest & Fair Business

Cardiol Therapeutics Inc. has a comprehensive Whistleblower Policy, revised in July 2021, which applies to all directors, officers, employees, key consultants, and advisors.

It allows for confidential and anonymous submission of concerns via written communication or telephone, and explicitly prohibits retaliation against individuals making good-faith reports. The policy is annually reviewed by the Audit Committee, and all related documents are retained for seven years. Six of the eight nominated directors are considered independent, meaning 75% of the board is free from material conflicts of interest. The company has adopted a written Code of Business Conduct and Ethics that applies to directors, officers, and employees, addressing conflicts of interest, fair dealing, and compliance with laws. The Audit Committee annually reviews the anti-fraud, anti-bribery, anti-corruption, and risk assessment programs.

Kind to Animals

Cardiol Therapeutics Inc. is not cruelty-free due to engaging in animal testing.

Preclinical studies in animals are required to demonstrate the safety and efficacy of its product candidates before marketing approval from regulatory authorities. There is no information provided about the use of alternative testing methods for the company's products. The company's policy indicates that legal mandates for animal testing override alternatives. While no specific animal testing volume is provided for Cardiol Therapeutics, the company is listed as engaging in animal testing, and the industry context suggests a high volume of animals used annually for biomedical research. The company's research and development expenses were $3,530,183 in 2019, $10,870,421 in 2021, $18,962,080 in 2022, and $14,224,287 in 2023. However, there is no specific percentage of this R&D budget allocated to animal-free technologies.

Planet-Friendly Business

The provided articles explicitly state that the content is a directory of filings and does not contain any ESG data for Cardiol Therapeutics Inc.

Consequently, no quantitative data, regulatory actions, certifications, or other specific facts related to environmental performance could be extracted to assess any of the KPIs.

Safe & Smart Tech

Cardiol Therapeutics' privacy policy states that users can unsubscribe from emails and request access to or correction of their data, which aligns with industry-standard user privacy controls.

The company's 2023 Form 20-F mentions compliance with various regulations, including FDA and Health Canada, and its privacy policy states compliance with Canadian law. This indicates basic compliance with applicable regulations, typical for the industry. No specific evidence was found for data breaches, cybersecurity investment, AI ethics, encryption, or other security and privacy practices.

Zero Waste & Sustainable Products

No specific, concrete data points or initiatives related to waste management, product recyclability, packaging sustainability, or other zero waste and sustainable product metrics for CRDL.US were found in the provided articles. Article 1 pertains to AstraZeneca.

and the other articles do not contain relevant information for CRDL.US regarding this ethical value.